The use of TRT, however, provides an opportunity to treat all sites of disease, and the approvals of Ra-223 and 177Lu-PSMA-617 for mCRPC provide evidence that these approaches have a role in the treatment of metastatic disease. Here, FOLH1 is linked to metastatic neoplasm.